Information Provided By:
Fly News Breaks for July 23, 2018
INSM
Jul 23, 2018 | 05:07 EDT
Goldman Sachs analyst Dana Flanders started Insmed with a Neutral rating and $32 price target. The analyst is taking a more conservative stance on the initial launch of Alis relative to consensus estimates. Flanders does, however, see a high unmet need in treating nontuberculous mycobacterial lung disease.
News For INSM From the Last 2 Days
INSM
INSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.